Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Saved in:
| Title: | Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. |
|---|---|
| Authors: | Hanada K; Laboratory of Stem Cell Regulation, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Fukasawa K; Laboratory of Stem Cell Regulation, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Hinata H; Laboratory of Stem Cell Regulation, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Imai S; Laboratory of Stem Cell Regulation, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Takayama K; Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.; Department of Environmental Biochemistry, Kyoto Pharmaceutical University, Kyoto, Japan., Hirai H; Laboratory of Stem Cell Regulation, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Ohfusa R; Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Hayashi Y; Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Itoh F; Laboratory of Stem Cell Regulation, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. |
| Source: | Cancer science [Cancer Sci] 2022 Oct; Vol. 113 (10), pp. 3547-3557. Date of Electronic Publication: 2022 Aug 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1349-7006 |
|---|---|
| DOI: | 10.1111/cas.15491 |
